Sana Biotechnology has announced the successful use of fusogen technology to deliver potent in vivo gene editing of human hematopoietic stem cells (HSCs). Published in Nature Biotechnology, the preclinical research highlights systemic delivery in murine models, demonstrating promising precision for bone marrow–based therapies.